BRO Outperforms Industry, Trades at Premium: How to Play the Stock

Brown & Brown (BRO) shares have outperformed the market, gaining 15.7% in the past year, driven by robust earnings growth of 21.5% over five years and a strategic acquisition-led expansion, including 32 deals in 2024. The insurer demonstrates strong fundamentals with 30 consecutive years of dividend increases and positive growth projections for 2025 and 2026, with analysts forecasting a 12.6% upside. However, BRO's shares are trading at a premium valuation of 24.53x forward earnings, exceeding the industry average, leading to a Zacks Rank #3 (Hold) recommendation suggesting caution for new positions.

Analysis

Brown & Brown, Inc. (BRO) presents a clear case of strong operational performance contrasted with a premium valuation. The company has delivered a 15.7% share price gain over the past year, outperforming its industry and the broader market, supported by a five-year earnings growth rate of 21.5% that surpasses the industry average of 15.2%. This growth is heavily fueled by a disciplined and aggressive acquisition strategy, with 687 acquisitions completed since 1993 and 32 in 2024 alone. This M&A activity, combined with organic growth from strong client retention and favorable insurance rates, has led to robust top-line performance and an industry-leading adjusted EBITDAC margin. The firm's financial health is further evidenced by a strong capital position and a 30-year history of consecutive dividend increases, which have grown at an 8.7% CAGR since 2019. Forward-looking consensus estimates reinforce this positive outlook, projecting 8.8% EPS and 8.1% revenue growth for 2025, with analyst price targets suggesting a potential 12.6% upside. However, the primary point of caution is the stock's valuation; its price-to-forward earnings multiple of 24.53X stands notably above the industry average of 21.24X, signaling that the market has already priced in much of this operational excellence.

Key Decisions for Investors

• Given the company's strong fundamentals, consistent dividend growth, and positive analyst outlook, current long-term investors may find it reasonable to hold their positions, viewing the premium valuation as justified by superior execution.
• Prospective investors should be cautious of the elevated valuation, as its 24.53X forward P/E is significantly above the industry average, and may consider waiting for a market pullback to find a more attractive entry point.
• Investors should closely monitor the company's ability to successfully integrate its acquisitions and maintain its industry-leading margins, as these factors are critical to justifying its premium valuation and sustaining growth.
• For those seeking exposure to the insurance brokerage sector at a lower relative cost, an evaluation of peers like Willis Towers Watson (WTW), noted to be trading at a discount, could present a viable alternative.